INTERVIEW innovation or market expansion do you plan to prioritise in the coming years? In terms of innovation, we will make sure to keep striving in the areas where we already have demonstrated leadership (Solid State R&D, Process Development, Purification & Crystallisation Development) and will push the envelope to offer downstream services such as manufacturing of GMP batches for clinical trials, pre-formulation studies and formulation development. In terms of market expansion, we also clearly want to focus in the USA market where we already have a significant footprint. The USA is a global leader in investment and innovation within the biotechnology and pharmaceutical industries, and there is a strong appreciation for high-quality RD services, particularly those that integrate expertise in synthetic and solidstate chemistry. This is especially relevant in niche sectors such as Highly Potent Active Pharmaceutical Ingredients (HAPIs), where Enantia’s specialised capabilities and experience positions the company to deliver significant value. How will Enantia’s customers benefit from the acquisition by INVACO? Are there any immediate changes or enhancements to your products or services that customers can expect? The benefit for our customers will become visible in a few months’ time, according to the plan. The final goal as INNVACO is to put together a lean organisation that offers swift and quality services to the pharma and biotech sectors. The ultimate goal of INVACO is to put under one roof the best of the CRO and CMO approaches and expertise, something that we believe is a major gap right now. Enantia had a significant presence at Drug Discovery Chemistry Europe 2024, DCAT and CPhi. Can you share some key insights or breakthroughs discussed during the events and how they align with Enantia’s mission to drive innovation in the industry? Letting aside the discussions about how AI will shape this business going forward, we had a number of discussions with our customers on how to speed up the process from pre-clinical candidate all along to first-inhuman batches. This interest was major when this involves products such as HAPI, controlled substances or new modalities, posing some additional challenges over the standard workflows and timelines. Enantia has been recognised for its contributions to the purification of high-value compounds from complex matrixes of either natural or synthetic origins. What do you believe sets Enantia apart as a leader in this space and how do you plan to maintain this leadership position in the face of evolving industry challenges? You are making a good point, and yes, we have made great contributions to this area, to the point that we have examples of customers that have completely changed their established purification processes for existing commercial products and adopted Enantia’s developed approaches because these are, simply put, much more efficient. Here, we leverage the quite unique expertise we have in finding new solid forms of small molecules to develop scalable purification and resolution processes. So, when a company needs to improve the efficiency of their process with purification challenges, I would definitely recommend them talking to us. A hot topic for us right now is the crystallisation of new modalities, such as oligopeptides, cyclopeptides and other larger and flexible molecules. We believe that we can offer innovative solutions to crystallise these products either to purify them or to formulate them as crystalline phases rather than amorphous forms. Looking ahead, what is your long-term vision for Enantia under INVACO’s ownership? How do you plan to maintain Enantia’s identity while leveraging the strengths of the larger organisation? Our long-term vision for Enantia under the new ownership is to continue building on the strong foundation that has defined us over the last 20 years. We will remain committed to delivering exceptional quality, fostering a customer-driven mentality, driving innovation and ensuring the applicability of our processes to large-scale production. At the same time, being part of a larger organisation presents exciting opportunities to enhance our offerings by expanding our capabilities to address additional downstream needs of our customers throughout the drug development process. From preclinical to clinical development, our goal is to provide comprehensive solutions that ease their journey, support their challenges and accompany them every step of the way. We aim to create even greater value for our customers and strengthen our position as a trusted partner in the pharmaceutical and biotech industries. 49 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025
RkJQdWJsaXNoZXIy MjY2OTA4MA==